Femasys Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kathy Lee-Sepsick
- Full Time Employees
- 54
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 3950 Johns Creek Court Suwanee GA United States of America 30024
- IPO Date
- Jun 18, 2021
- CIK
- 0001339005
- Website
- femasys.com
- Similar Companies
- Business
- Femasys Inc. Femasys Inc. is a biomedical company focused on transforming women's healthcare worldwide by developing novel, minimally invasive, in-office therapeutic and diagnostic solutions for reproductive health, including permanent birth control, infertility treatment, and cervical assessments. The company offers FemBloc, a non-surgical permanent birth control system that delivers a degradable biopolymer to block both fallopian tubes; FemaSeed, a directed artificial insemination device for infertility treatment that places sperm intratubally; FemVue, a saline-air contrast ultrasound for fallopian tube evaluation; FemCerv, an endocervical tissue sampler for cervical cancer screening; FemCath, an intrauterine catheter for diagnostic procedures; and FemChec, a hysteroscopy alternative for uterine evaluations; with recent additions including the FemSperm product family comprising Setup Kit, Insemination Prep Kit, and Analysis Kit for in-office sperm preparation and analysis. Femasys Inc. operates primarily in the United States and pursues global expansion in Europe and other regions, targeting gynecologists and women's health providers with accessible alternatives to surgical interventions. Founded in 2004 and headquartered in Suwanee, Georgia, the company commercializes FDA-cleared products like FemVue while advancing regulatory approvals for its pipeline. Recent developments include securing CE Mark approval in 2024 for FemaSeed, FemVue, FemCerv, and FemCath to enable European sales; establishing distribution partnerships such as with Kebomed in September 2025 for FemBloc commercialization in France and Benelux, and with Comercialico Quirurgica and Durgalab in Spain earlier in 2025; partnering with Medical Electronic Systems in September 2025 to launch the FemSperm Analysis Kit, completing its infertility portfolio; and receiving a second partner order for FemBloc in Europe to accelerate global growth.
Femasys Regains Compliance with Nasdaq Listing Requirements
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
Financial Analysis: CRISPR Therapeutics (NASDAQ:CRSP) and Femasys (NASDAQ:FEMY)
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Femasys (NASDAQ:FEMY) Stock Price Up 0.1% – What’s Next?
Reviewing Femasys (NASDAQ:FEMY) and Response Genetics (OTCMKTS:RGDXQ)
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys Revenue Jumps 85 Percent in Q2
Femasys Announces Second Quarter Financial Results for 2025